

Interim Job Aid for Mpox Post Exposure Prophylaxis (PEP):

Part 1- Product Information

This Job Aid is **only** for use if the Chicago Department of Public Health has already approved of administering vaccination. For questions about mpox post exposure prophylaxis administration, please reach out to monkeypoxpep@cityofchicago.org.

Product Information: Jynneos Vaccine

(For further details, please see attached package insert.)

Jynneos is a live, non-replicating vaccine labeled for smallpox and mpox virus.

Indications and eligibility for PEP:

The mpox Jynneos vaccine is available to anyone living in Illinois who:

- Had skin-to-skin or intimate contact (e.g., household members with close physical contact or intimate partners) with someone diagnosed with mpox.
- Exchanges goods or services for sex.
- Lives with HIV, especially persons with uncontrolled or advanced HIV disease,
- Is eligible for or is currently taking PrEP (pre-exposure prophylaxis) to help prevent infection with HIV.

OR Is a sexually active bisexual, gay and other same gender-loving men, or sexually active transgender individuals.

OR Sexual partners of those included above, or individuals who anticipate meeting criteria above in the future.

Especially consider vaccinating patients who:

Met recent partners through online applications or social media platforms (such as Grindr, Tinder or Scruff), or at clubs, raves, sex parties, saunas.

Were diagnosed with sexually transmitted infection(s) (STI) in past 6 months.


Preparation and Administration:

Jynneos is a suspension in a 0.5 ml vial.

- The standard regimen (FDA approved) is 0.5 ml subcutaneous administration.
- The alternative regimen (approved for emergency use on 8.9.22) is 0.1 ml intradermal administration. This allows for additional availability of vaccine to a larger population while maintaining similar immunogenicity to the SQ administration. [Evidence for ID Administration of Jynneos](#).
- CDPH supports administration as follows:

- 0.1ml intradermal administration (alternative regimen) for **adults age 18 and over**.
- 0.5 ml subcutaneous administration (standard regimen) for minors **age 17 and younger**.
 - When using the standard regimen, there is no lower age limit
- With both routes of administration, CDPH recommends administration of 2 doses, no sooner than 28 days apart for both PEP and PEP ++
 - If dose 1 was administered subcutaneously, it is appropriate to administer dose 2 intra-dermally.

Intradermal Injection Process: (See [video](#) for training.)



- For intradermal injection: use a tuberculin syringe with a 27 gauge, 1/4 to 1/2" needle with a short bevel. Always use a new, sterile needle and syringe for each injection.
- For subcutaneous injection: use sterile syringe with a 23–25 gauge, 5/8" needle.
- Intradermal injection should be administered to the volar (inner arm). If individuals are concerned about scarring in the region of the vaccine, the alternative option of vaccinating below the scapula can be used.
 - *When necessary in eligible individuals, the dosing regimens are interchangeable. For example, a person aged 18 years or older who received one JYNNEOS vaccine dose with the standard subcutaneous regimen may receive a second dose with the alternative intradermal regimen at the recommended interval (i.e., 28 days) to complete the vaccination series. Another example is a person who received the*

first dose intradermally, had a robust local reaction, and refuses a second dose unless given subcutaneously. In this situation, that second dose can be given subcutaneously.

- *Healthcare providers should determine the medical history of recipients to appropriately decide whether to administer the vaccine subcutaneously or intradermally. **Healthcare providers should be ready to administer via both routes, in case patients are unable or unwilling to receive vaccine intradermally.***
- If swelling occurs from the first to second administration, administer next dose in contralateral arm or below the scapula.
- If you realize you have given an expired dose by accident, please give a new dose as soon as possible.
- If have questions about troubleshooting, please see [Vaccine Administration Errors](#) for more information.
 - Bavarian Nordic contact information:

 - Email: medical.information_US@bavarian-nordic.com
 - U.S. phone number: 1-844-422-8274
 - U.S. fax number: 1-843-422-8274

Side effects:

- Minimal side effects have been reported, but most commonly include:
 - Injection site pain, redness, and swelling,
 - Muscle pain, headache, fatigue
 - [For intradermal injection](#), higher risk of erythema, induration, itchiness, and pain at injection site, in comparison to SQ administration.
 - Patients with suspected adverse events should visit their healthcare provider, and their symptoms should be reported through [VAERS](#).

Contraindications:

- If the individual has previously had a history of severe allergies, particularly to vaccines, their risk for contracting mpox should be evaluated.
- Side effects in individuals living with HIV and severe atopic dermatitis were comparable to those for healthy adults.
- If an individual has a history of keloid formation, it is recommended to administer subcutaneously.

Storage:

Please see updated package insert (attached).

- Jynneos may be stored at 2-8°C for up to 8 weeks. NOTE: This is an update to the original package insert that requires storage at -20°C
- Unpunctured vials may be stored at room temperature for 6 cumulative hours.
- Punctured vials may be stored in the refrigerator for up to 8 hours.

Direct patients to [Jynneos Patient Fact Sheet](#) for further Q and A.

For additional information including package inserts and sample standing orders visit:

Job Aid for Healthcare Workers Administering Mpox Post Exposure Prophylaxis (PEP): Part 2- Reporting

Reporting to CDPH

Prior to receipt of the vaccine, providers will be required to sign and return an “Mpox Virus Vaccine Provider Agreement” to CDPH, indicating their willingness to report in ICARE.

Reporting in ICARE

- If you have an HL7, the administration of Jynneos can be entered into ICARE directly from your EMR.
- Alternatively, Jynneos administration can be entered into the “Other” part of ICARE, as seen below:

Site Name: IMMUNIZATION PROGRAM AT WSCDC

Add Shots As: ☒ Current (with lots from inventory)

Visit 1	Visit 2	Visit 3
06/17/2022		
<input type="checkbox"/> DTP <input type="checkbox"/> HIB <input type="checkbox"/> HAV <input type="checkbox"/> HBV <input type="checkbox"/> HPV <input type="checkbox"/> FLU <input type="checkbox"/> H1N1 <input type="checkbox"/> MMR <input type="checkbox"/> MEN <input type="checkbox"/> MEN-B <input type="checkbox"/> PNE <input type="checkbox"/> POL <input type="checkbox"/> ROT <input type="checkbox"/> Tdap <input type="checkbox"/> Td <input type="checkbox"/> VAR <input type="checkbox"/> ZOS <input type="checkbox"/> COVID-19 <input checked="" type="checkbox"/> Other	<input type="checkbox"/> DTP <input type="checkbox"/> HIB <input type="checkbox"/> HAV <input type="checkbox"/> HBV <input type="checkbox"/> HPV <input type="checkbox"/> FLU <input type="checkbox"/> H1N1 <input type="checkbox"/> MMR <input type="checkbox"/> MEN <input type="checkbox"/> MEN-B <input type="checkbox"/> PNE <input type="checkbox"/> POL <input type="checkbox"/> ROT <input type="checkbox"/> Tdap <input type="checkbox"/> Td <input type="checkbox"/> VAR <input type="checkbox"/> ZOS <input type="checkbox"/> COVID-19 <input type="checkbox"/> Other	<input type="checkbox"/> DTP <input type="checkbox"/> HIB <input type="checkbox"/> HAV <input type="checkbox"/> HBV <input type="checkbox"/> HPV <input type="checkbox"/> FLU <input type="checkbox"/> H1N1 <input type="checkbox"/> MMR <input type="checkbox"/> MEN <input type="checkbox"/> MEN-B <input type="checkbox"/> PNE <input type="checkbox"/> POL <input type="checkbox"/> ROT <input type="checkbox"/> Tdap <input type="checkbox"/> Td <input type="checkbox"/> VAR <input type="checkbox"/> ZOS <input type="checkbox"/> COVID-19 <input type="checkbox"/> Other


Select an Action:

Summary Details


Show Lots: ☒ All ☐ Vfc ☐ Private ☐ 317

Shot Date	Group	Vaccine/Lot	Provider/Vaccinator	VFC/VIS Status	Body Site/Route
<input checked="" type="checkbox"/> 06/17/2022	Other	JYNNEOS [BN]		Eligibility not determined/unknown [V00]	
		123456 (Private)		Select VIS	


Reporting Wastage in ICARE:



From the vaccines tab, click on the lot number you wish to edit



Click "Add Transaction"



Select "Wasted"